| Prev Close: | 27.21 |
|---|---|
| Open: | 27.78 |
| Bid: | 20.21 x 500 |
| Ask: | 33.00 x 200 |
| 1y Target Est: | 30.75 |
| Beta: | 1.79 |
| Next Earnings Date: | 5-Aug-13 |
| Day's Range: | 27.04 - 27.89 |
|---|---|
| 52wk Range: | 9.78 - 28.68 |
| Volume: | 520,072 |
| Avg Vol (3m): | 441,722 |
| Market Cap: | 1.71B |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.94 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alnylam announces proof-of-concept data from RNAi programtheflyonthewall.com(Fri May 17)
- Alnylam announces proof-of-concept data from RNAi programat theflyonthewall.com(Fri May 17)
- InPlay: Alnylam Pharma presents key pre-clinical proof-of-concept data for ALN-AS1; RNAi therapeutics targeting ALAS-1 completely block production of toxic heme biosynthesis intermediates that cause symptoms and disease pathologyBriefing.com(Fri May 17)
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of PorphyriaBusiness Wire(Fri May 17)
- Alnylam Pharmaceuticals' CEO Presents at 2013 Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Thu May 16)
- Alnylam to Webcast Presentation at 2013 UBS Global Healthcare ConferenceBusiness Wire(Wed May 15)
- ALNYLAM PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Tue May 14)
- Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care ConferenceBusiness Wire(Wed May 8)
- ALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue May 7)
- Alnylam Narrows Loss, Sales FallZacks(Tue May 7)
- Alnylam Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Mon May 6)
- Alnylam takes smaller 1Q loss on lower costsAP(Mon May 6)
- Alnylam Pharmaceuticals Earnings: Here’s Why Investors are Excited Nowat Wall St. Cheat Sheet(Mon May 6)
- Alnylam Pharmaceuticals Reports First Quarter 2013 Financial ResultsBusiness Wire(Mon May 6)
- ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Mon May 6)
Press Releases
- Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of PorphyriaBusiness Wire(Fri May 17)
- Alnylam to Webcast Presentation at 2013 UBS Global Healthcare ConferenceBusiness Wire(Wed May 15)
- Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care ConferenceBusiness Wire(Wed May 8)
Must Read
- Taxes on some wealthy French top 100 percent of income - paperReuters(1969-12-31T18:59:59GMT-05:00)
- Even before first drops flow, Uganda's oil beset by bribery charges, political interferenceThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Exclusive: EU cites Chinese telecoms Huawei and ZTE for trade violationsReuters(1969-12-31T18:59:59GMT-05:00)
- Top officials seek to address euro currency's institutional failings, seek end to IMF roleThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Popular 'Sonic the Hedgehog' video games coming to Nintendo systemsThe Canadian Press(1969-12-31T18:59:59GMT-05:00)